Abivax SA American Depositary Shares
$ 110.64
-0.26%
04 Dec - close price
- Market Cap 8,187,962,000 USD
- Current Price $ 110.64
- High / Low $ 112.56 / 107.06
- Stock P/E N/A
- Book Value -0.76
- EPS -3.58
- Next Earning Report 2025-12-15
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.58 %
- ROE -5.00 %
- 52 Week High 130.25
- 52 Week Low 4.77
About
None
Analyst Target Price
$123.78
Quarterly Earnings
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-09-08 | 2025-06-02 | 2025-03-24 | 2024-11-07 | 2024-09-09 | 2024-04-02 | 2024-02-06 | 2023-11-29 | 2023-09-21 |
| Reported EPS | -0.89 | -0.95 | -0.8143 | -0.72 | -1.01 | -0.7903 | 0 | -0.64 | -0.72 |
| Estimated EPS | -0.95 | -0.76 | -1.29 | -0.79 | -0.97 | -0.6 | -0.92 | -0.64 | 0 |
| Surprise | 0.06 | -0.19 | 0.4757 | 0.07 | -0.04 | -0.1903 | 0.92 | 0 | -0.72 |
| Surprise Percentage | 6.3158% | -25% | 36.876% | 8.8608% | -4.1237% | -31.7167% | 100% | 0% | None% |
Next Quarterly Earnings
| Sep 2025 | |
|---|---|
| Reported Date | 2025-12-15 |
| Fiscal Date Ending | 2025-09-30 |
| Estimated EPS | -0.68 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABVX
2025-11-02 11:53:57
Hedge funds that invest in biotech stocks experienced significant gains thanks to the obscure French drugmaker Abivax. The company's U.S.-listed shares surged over 580% in one day after releasing positive late-stage trial results for its inflammatory bowel disease drug, increasing its market value from around $500 million to over $6 billion. This provided a substantial boost for biotech-focused funds previously facing anemic returns.
2025-10-19 07:23:38
Barclays initiated coverage on ABIVAX Société Anonyme (NASDAQ:ABVX) with an Overweight rating and a $142 price target, citing favorable risk/reward in de-risked biotech investments and market preference for new treatments. This follows Guggenheim's reiterated Buy rating with a $150 price target. ABIVAX is a clinical-stage biotechnology company focused on antiviral compounds and therapeutic vaccines for severe infectious diseases.
2025-10-18 00:45:54
ABIVAX Société Anonyme announced positive Phase 3 clinical data for obefazimod in ulcerative colitis, meeting FDA primary endpoints for clinical remission and showing a favorable safety profile. This data strengthens the company's investment narrative by bolstering regulatory submission plans and potentially improving its negotiating position for partnerships or funding. Despite this progress, funding needs and regulatory uncertainties remain key concerns for investors.
2025-10-18 00:45:53
ABIVAX Société Anonyme announced positive Phase 3 clinical data for obefazimod in ulcerative colitis, showing clinically meaningful improvements and meeting FDA primary endpoints for clinical remission. This data strengthens the company's regulatory submission plans and could accelerate partnerships, addressing investor concerns about efficacy and safety, although funding and regulatory uncertainties persist.
2025-10-15 16:02:00
Abivax shares closed up 3.25% at 76.3 euros, continuing a short-term upward trend with a 6.12% gain over the last seven days and an exceptional 778% performance over the past year. This surge follows positive results from its Phase 3 clinical trials for Obefazimod, a drug candidate for ulcerative colitis. While technical indicators suggest bullish momentum, some flow indicators advise caution as buying volumes remain moderate.
2025-10-14 12:41:43
ABIVAX Société Anonyme is rated a Strong Buy with a $105 price target, primarily due to the potential of its drug Obefazimod as a best-in-class treatment for ulcerative colitis (UC). The company shows robust efficacy in early Phase 3 trials and targets a large, fast-growing market. Upcoming Phase 3 maintenance data in Q2 2026 is a significant catalyst, expected to drive substantial upside for ABIVAX shares.
